6 research outputs found
Seeing the Lianas in the Trees: Woody Vines of the Temperate Zone
Volume: 72Start Page: 2End Page: 1
To Burn Or Not To Burn Oriental Bittersweet: A Fire Manager’s Conundrum
Oriental bittersweet (Celastrus orbiculatus) is an introduced liana (woody vine) that has invaded much of the Eastern United States and is expanding west into the Great Plains. In forests, it can girdle and damage canopy trees. At Indiana Dunes, we have discovered that it is invading non-forested dune habitats as well. Anecdotal evidence suggests that fire might facilitate its spread, but the relationship between fire and this aggressive invader is poorly understood. We investigated four areas important to fire management of oriental bittersweet, each of which we will briefly summarize here. 1) What fire temperatures cause seed mortality? For seeds, temperatures above 140°C for three minute or more kills the embryo. For fruits, temperatures above 140°C kill the seeds inside after five minutes. While oriental bittersweet fruits ripen in October and November, the seeds are not dispersed until later in the early to mid December. Thus fall fires will not have any impact on the seeds unless perhaps if they are near the ground. Late winter and early spring fires are likely to kill seeds in the top litter at least. Thus spring fire can reduce the pool of seeds available to germinate. 2) Does fire modify habitat susceptibility to invasion? We found that post fire environment had no effect on the emergence and survival of oriental bittersweet, except that the tallest plants, after two years since sowing, were in the control plots. Highest establishment occurred in mesic silt loam prairie and oak forest. Survival was greatest in mesic prairie and greatest biomass occurred in the oak forest. 3) Both fire and cutting can cause oriental bittersweet to resprout and root sucker. Does the resprouting response differ between these two treatments and can a combination of cutting and pre- or post-fire treatment facilitate its removal? Cutting sometimes increased stem density between one and two times, but burning increased density by two or more times depending on the maximum fire temperature and duration. Cutting in early July reduced total nonstructural carbohydrates by 50% from normal July levels and 75% below dormant season levels. Thus burning established populations will only serve to increase their local density. 4) How does oriental bittersweet abundance vary with fire regime and can we predict the abundance of this species in a fire mosaic landscape based on fire return interval and time since last fire? At the landscape scale, we can predict the presence and abundance of oriental bittersweet, but have less success predicting its cover and distribution. The presence of oriental bittersweet was significantly negatively influenced by canopy closure, burn frequency, and distance to roads and railroads. In plots where C. orbiculatus was present, abundance was significantly greater in plots with low to moderate burn frequency, and marginally (p = 0.056) lower in plots with greater canopy cover. Both cover and distribution of C. orbiculatus was not significantly affected by the measured variables. These results suggest the frequent fire may be effective in preventing the establishment of oriental bittersweet
Observation of mycorrhizal colonization in roots in natural populations of Celastrus orbiculatus
Heterospecific pollination by an invasive congener threatens the native American bittersweet, Celastrus scandens.
Invasive plants have the potential to interfere with native species' reproductive success through a number of mechanisms, including heterospecific pollination and hybridization. This study investigated reproductive interactions between a native North American woody vine (American bittersweet, Celastrus scandens) and an introduced congener (oriental bittersweet, C. orbiculatus). The decline of C. scandens in the eastern portion of its range is coincident with the introduction and spread of C. orbiculatus, and the two species are known to hybridize. The relationship between proximity and floral production of conspecific and heterospecific males on fertilization and hybridization rates was measured at a field site in northwestern Indiana, USA where both species occur and reproduce. We found that the invasive vine had an extreme advantage in both male and female floral production, producing nearly 200 times more flowers per staminate plant and 65 times more flowers per pistillate plant than the native. Using nuclear microsatellite DNA markers we found that hybridization rates were asymmetric; 39% of the C. scandens seeds tested were hybrids, compared to only 1.6% of C. orbiculatus seeds. The asymmetric hybridization rates were likely not solely due to greater abundance of C. orbiculatus pollen because experimental hand crosses revealed that C. scandens had a higher rate (41%) of heterospecific fertilization than C. orbiculatus (2.4%). We previously reported that few hybrids were observed in the wild, and hybrids had greatly reduced fecundity. Thus, in our system, the threat posed by heterospecific pollen is not replacement by hybrids or introgression, but rather asymmetric reproductive interference. Reproductive interference extended to distances as great as 100 meters, thus, efforts to conserve the native species must reduce its exposure to C. orbiculatus over a relatively large spatial scale
Recommended from our members
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19.
In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978.
Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90.
Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19.
US National Institutes of Health and Operation Warp Spee